87 related articles for article (PubMed ID: 21597699)
1. A novel methotrexate-albumin (mtx-rsa)-conjugate causes significant growth delay of o-342 ovarian-carcinoma in-vivo.
Steinmann A; Friedrich E; Rath U
Oncol Rep; 1995 Jan; 2(1):107-9. PubMed ID: 21597699
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.
Stehle G; Wunder A; Sinn H; Schrenk HH; Schütt S; Frei E; Hartung G; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Oct; 8(9):835-44. PubMed ID: 9402310
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Apr; 10(4):405-11. PubMed ID: 10378676
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.
Wunder A; Stehle G; Schrenk HH; Hartung G; Heene DL; Maier-Borst W; Sinn H
Int J Cancer; 1998 Jun; 76(6):884-90. PubMed ID: 9626357
[TBL] [Abstract][Full Text] [Related]
5. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Stehle G; Sinn H; Wunder A; Schrenk HH; Schütt S; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Aug; 8(7):677-85. PubMed ID: 9311444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats.
Kremer P; Hartung G; Bauder-Wüst U; Schrenk HH; Wunder A; Heckl S; Zillmann U; Sinn H
Anticancer Drugs; 2002 Jul; 13(6):615-23. PubMed ID: 12172507
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
8. Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosylated albumins.
Han J; Lim SJ; Lee MK; Kim CK
Drug Deliv; 2001; 8(3):125-34. PubMed ID: 11570592
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
11. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
12. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice.
Taheri A; Dinarvand R; Ahadi F; Khorramizadeh MR; Atyabi F
Int J Pharm; 2012 Jul; 431(1-2):183-9. PubMed ID: 22531853
[TBL] [Abstract][Full Text] [Related]
13. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.
Bures L; Bostík J; Motycka K; Spundová M; Rehák L
Neoplasma; 1988; 35(3):329-42. PubMed ID: 3405341
[TBL] [Abstract][Full Text] [Related]
14. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.
Weigand M; Hartung G; Roboz J; Sieger S; Wolf M; Sinn H; Schrenk HH; Wiessler M; Frei E
Anticancer Drug Des; 2001; 16(4-5):227-37. PubMed ID: 12049481
[TBL] [Abstract][Full Text] [Related]
15. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Chemother Pharmacol; 1996; 38(6):499-507. PubMed ID: 8823490
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate).
Suksiriworapong J; Taresco V; Ivanov DP; Styliari ID; Sakchaisri K; Junyaprasert VB; Garnett MC
Colloids Surf B Biointerfaces; 2018 Jul; 167():115-125. PubMed ID: 29631222
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate-albumin and aminopterin-albumin effectively prevent experimental acute graft-versus-host disease.
Wolff D; Frei E; Hofmeister N; Steiner B; Kleine HD; Junghanss C; Sievert K; Terpe H; Schrenk HH; Freund M; Hartung G
Transplantation; 2006 Aug; 82(4):527-33. PubMed ID: 16926597
[TBL] [Abstract][Full Text] [Related]
18. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
Deguchi T; Chu TM; Leong SS; Horoszewicz JS; Lee CL
Cancer Res; 1986 Aug; 46(8):3751-5. PubMed ID: 3731053
[TBL] [Abstract][Full Text] [Related]
19. TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.
Laquintana V; Denora N; Cutrignelli A; Perrone M; Iacobazzi RM; Annese C; Lopalco A; Lopedota AA; Franco M
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27322261
[TBL] [Abstract][Full Text] [Related]
20. Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier.
Nevozhay D; Budzynska R; Kanska U; Jagiello M; Omar MS; Boratynski J; Opolski A
Anticancer Res; 2006; 26(2A):1135-43. PubMed ID: 16619515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
